Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050960 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 612
- Enrollment target
NCT00050960 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 612 participants.
The verdict
NCT00050960, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 612 participants
- Enrollment target
Study Summary
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.
Interventions
- DRUG bexarotene with carboplatin and paclitaxel
- DRUG carboplatin and paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 612 participants |
| Start Date | 2002-05 |
| Est. Completion | 2005-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050960
The ClinicalTrials.gov registry entry for NCT00050960 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 612 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bexarotene with carboplatin and paclitaxel is the first listed.
NCT00050960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050960 about?
NCT00050960 is a clinical study titled "Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer". This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.
What is the current status of trial NCT00050960?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 612 participants. The study started on 2002-05. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00050960?
The interventions under investigation include: bexarotene with carboplatin and paclitaxel (DRUG), carboplatin and paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00050960?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.